Phase III REST-ON trial supports benefit of Avadel's FT218 in narcolepsy

16 June 2021

Ireland-incorporated Avadel Pharmaceuticals (Nasdaq: AVDL) has announced new post hoc analyses of data from the completed pivotal Phase III REST-ON clinical trial of FT218, at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS), a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.

FT218 is currently under review at the US Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021.

If approved, FT218 will be the first and only oxybate medication intended to be taken just once at bedtime, offering patients a new, more intuitive approach to obtaining safe, uninterrupted sleep throughout the night.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK